Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?

British Journal of Dermatology

Volumn 170, Issue 5, 2014, Pages 1198-1199

  Tauber, M ^a,b   Viguier, M ^b   Le Gall, C ^a   Smahi, A ^a   Bachelez, H ^a,b  

^a IMAGINE INSTITUTE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN RECEPTOR;

CYTOKINE PRODUCTION; DEFICIENCY OF INTERLEUKIN 36 RECEPTOR ANTAGONIST; DNA FLANKING REGION; DRUG EFFICACY; EXON; FEEDBACK SYSTEM; GENOTYPE; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PUSTULAR PSORIASIS; SYSTEMIC THERAPY; TRANSGENICS; TREATMENT FAILURE; CASE REPORT; DEFICIENCY; MALE;

ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RECEPTORS, INTERLEUKIN;

EID: 84901008577     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12805     Document Type: Letter

References (10)

1. Hüffmeier U, Wätzold M, Mohr J, et al,. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014; 170: 202-4.
2. Rossi-Semerano L, Piram M, Chiaverini C, et al,. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013; 132: e1043-7.
3. Marrakchi S, Guigue P, Renshaw BR, et al,. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
4. Onoufriadis A, Simpson MA, Pink AE, et al,. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89: 432-7.
5. Viguier M, Aubin F, Delaporte E, et al,. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol 2012; 148: 1423-5.
6. Viguier M, Guigue P, Pagès C, et al,. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153: 66-7.
7. Blumberg H, Dinh H, Trueblood ES, et al,. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007; 204: 2603-14.
8. Tortola L, Rosenwald E, Abel B, et al,. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012; 122: 3965-76.
9. Towne JE, Sims JE,. IL-36 in psoriasis. Curr Opin Pharmacol 2012; 12: 486-90.
10. Aksentijevich I, Masters SL, Ferguson PJ, et al,. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.